[email protected]/(408) 457-3700

About Visgo Therapeutics, Inc.

Visgo Therapeutics was founded to develop new therapies to treat the large, underserved market of joint disease such as osteoarthritis (OA). We have developed a proprietary, joint friendly microparticle that can be loaded with drugs and delivered by intra-articular (IA) injection for release over time within the joint, with minimal systemic exposure. With this direct delivery, a low dose of drug in a single injection given at a physician’s office once a quarter will have similar or better efficacy as large daily oral doses of the drug. OA is a disease that occurs within the joints when the protective cartilage degenerates over time due to wear and tear or injury, and now affects more than 20 million in the US alone. There are few effective products on the market or in development to modify disease progression or treat pain associated with OA. Many therapies for OA have failed in clinical trials due to rapid clearance from the joint and/or systemic side effects before efficacy could be evaluated. Oral non-steroidal anti-inflammatory drugs (NSAIDs) are a first line of therapy for OA knee pain, but these drugs have serious systemic side effects. Visgo’s first product, VG201, delivers a very small quantity of a potent proven NSAID over time within the knee joint via a single IA injection. We have data demonstrating in vivo tolerance and extended drug release with a VG201 prototype, as well as particle and drug residence in the synovial membrane. The FDA has issued Visgo a pre-IND number, and confirmed that VG201 can be developed under its rapid 505(b)(2) pathway for new formulations of approved drugs. We expect to file our IND in Q4 2016. The US market size for VG201 is expected to be at least as large as the current annual $700m IA viscosupplementation market.

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

Location:
Burlington
Markets:
Pharmaceuticals
Therapeutic Areas:
Orthopedics